Patient characteristics in groups with and without MR toxicity
Variable . | Total (n = 148) . | No toxicity (n = 115) . | Toxicity* (n = 33) . | P . | |||
---|---|---|---|---|---|---|---|
No. . | % . | No. . | % . | No. . | % . | ||
Mean age at diagnosis, y (± SD) | 60 ± 13 | 61 ± 13 | 57 ± 15 | .19 | |||
Male sex | 69 | 47 | 56 | 49 | 13 | 39 | .43 |
Diagnosis | .09 | ||||||
Follicular lymphoma | 122 | 82 | 95 | 82 | 27 | 82 | |
Mantle cell lymphoma | 14 | 10 | 8 | 7 | 6 | 18 | |
Marginal zone lymphoma | 9 | 6 | 9 | 8 | 0 | ||
Lymphoplasmacytic lymphoma | 3 | 2 | 3 | 3 | 0 | ||
Ann Arbor stage | .40 | ||||||
Limited (I-II) | 21 | 14 | 15 | 13 | 6 | 18 | |
Advanced (III-IV) | 127 | 86 | 100 | 87 | 27 | 82 | |
B symptoms | 19 | 13 | 17 | 15 | 2 | 6 | .25 |
Extranodal involvement | 96 | 65 | 73 | 63 | 23 | 70 | .54 |
Transformed | 21 | 14 | 17 | 15 | 4 | 12 | 1.00 |
Induction regimen | .046 | ||||||
R-CHOP/R-CVP | 83 | 56 | 70 | 61 | 13 | 39 | |
BR | 65 | 44 | 45 | 39 | 20 | 61 | |
No. of induction cycles | .13 | ||||||
4 | 6 | 4 | 3 | 3 | 3 | 9 | |
5 | 7 | 5 | 5 | 4 | 2 | 6 | |
6 | 135 | 91 | 107 | 93 | 28 | 85 | |
Response to induction | .21 | ||||||
Complete response | 102 | 69 | 76 | 67 | 26 | 79 | |
Partial response/stable disease | 45 | 31 | 38 | 33 | 7 | 21 | |
Maintenance schedule | .002 | ||||||
Every 2 mo | 41 | 28 | 24 | 21 | 17 | 52 | |
Every 3 mo | 107 | 72 | 91 | 79 | 16 | 49 |
Variable . | Total (n = 148) . | No toxicity (n = 115) . | Toxicity* (n = 33) . | P . | |||
---|---|---|---|---|---|---|---|
No. . | % . | No. . | % . | No. . | % . | ||
Mean age at diagnosis, y (± SD) | 60 ± 13 | 61 ± 13 | 57 ± 15 | .19 | |||
Male sex | 69 | 47 | 56 | 49 | 13 | 39 | .43 |
Diagnosis | .09 | ||||||
Follicular lymphoma | 122 | 82 | 95 | 82 | 27 | 82 | |
Mantle cell lymphoma | 14 | 10 | 8 | 7 | 6 | 18 | |
Marginal zone lymphoma | 9 | 6 | 9 | 8 | 0 | ||
Lymphoplasmacytic lymphoma | 3 | 2 | 3 | 3 | 0 | ||
Ann Arbor stage | .40 | ||||||
Limited (I-II) | 21 | 14 | 15 | 13 | 6 | 18 | |
Advanced (III-IV) | 127 | 86 | 100 | 87 | 27 | 82 | |
B symptoms | 19 | 13 | 17 | 15 | 2 | 6 | .25 |
Extranodal involvement | 96 | 65 | 73 | 63 | 23 | 70 | .54 |
Transformed | 21 | 14 | 17 | 15 | 4 | 12 | 1.00 |
Induction regimen | .046 | ||||||
R-CHOP/R-CVP | 83 | 56 | 70 | 61 | 13 | 39 | |
BR | 65 | 44 | 45 | 39 | 20 | 61 | |
No. of induction cycles | .13 | ||||||
4 | 6 | 4 | 3 | 3 | 3 | 9 | |
5 | 7 | 5 | 5 | 4 | 2 | 6 | |
6 | 135 | 91 | 107 | 93 | 28 | 85 | |
Response to induction | .21 | ||||||
Complete response | 102 | 69 | 76 | 67 | 26 | 79 | |
Partial response/stable disease | 45 | 31 | 38 | 33 | 7 | 21 | |
Maintenance schedule | .002 | ||||||
Every 2 mo | 41 | 28 | 24 | 21 | 17 | 52 | |
Every 3 mo | 107 | 72 | 91 | 79 | 16 | 49 |
Proportions were compared by using the χ2 method (and Fisher’s exact test) and continuous variables were compared by using the Student t test.
SD, standard deviation.
Any grade toxicity (see supplemental Table 1).